Who needs a lung transplant? A clinician's referral guide (India)

In my practice at KIMS Hospital, Electronic City, the most common question patients and families ask is: “Have we waited too long - or is it too early to even consider this?” Both questions matter. Referring too late costs lives; referring too early creates anxiety. I am Dr. Manjunath M Negigoudara - MBBS (Gold Medalist), MD (Pulmonary Medicine), DNB, FIP - and I am the Transplant Pulmonologist at KIMS Hospital, Electronic City, Bengaluru. This article explains, in plain language, who actually benefits from lung transplantation, how the decision is made, and the specific disease-by-disease triggers that should send a patient to a transplant clinic.

What lung transplantation does - and does not do

A lung transplant replaces one or both diseased lungs with healthy lungs from a deceased donor. It does not cure the underlying disease - the goal is to restore breathing, quality of life and longevity. Most patients return to school, work, and active life within 3-6 months of surgery, on lifelong immunosuppression.

Per the International Society for Heart and Lung Transplantation (ISHLT) registry, pooled global median survival is approximately 1-year 85%, 3-year 65%, 5-year 55%, and 10-year 32%. These are pooled international figures - individual outcomes depend heavily on age, disease, single vs bilateral, centre volume, and freedom from Chronic Lung Allograft Dysfunction (CLAD). High-volume programmes typically report at the upper end of these ranges.

In India, lung transplantation is now an established option at high-volume centres. The KIMS Electronic City thoracic transplant programme has completed 750+ transplants - among the largest in Asia - and Dr. Manjunath M Negigoudara has personally managed more than 250 lung transplant cases across evaluation, ECMO support, surgery, and long-term follow-up.

Who benefits - the common indications

The ISHLT 2021 candidate selection consensus lists the disease groups where lung transplant offers the strongest survival and quality-of-life benefit. In descending order of global frequency:

The trajectory matters more than the diagnosis

What ties these conditions together is not the diagnosis itself but the trajectory. A patient with IPF stable on antifibrotics may not need transplant for years; a patient with the same diagnosis whose 6-minute walk distance is dropping every 3 months and who needs increasing oxygen probably does. This is the calibration that a transplant pulmonologist adds: not just “is this patient sick?” but “is this patient on a curve that will run out of medical options in the next 12-24 months?”

The disease-specific referral triggers (this is where most physicians hesitate)

The single most common referral mistake I see is delay. General pulmonologists often wait until the patient is on continuous home oxygen or has been hospitalised twice before suggesting transplant. By that point, the wait for a suitable donor may exceed the patient’s remaining survival. Here are the specific triggers, disease by disease, drawn from the ISHLT 2021 consensus and the referral timing paper published in JHLT 2015.

COPD (including alpha-1 antitrypsin deficiency)

Use the BODE index - the validated composite score from the 2004 NEJM landmark paper that predicts COPD survival far better than FEV1 alone. It combines four variables:

Refer to a transplant clinic when the BODE score reaches 5-6. List when the score reaches 7-10 - this corresponds to roughly 15-20% four-year survival. Waiting for FEV1 alone to drop below 25% predicted often means referring 12-18 months too late.

Idiopathic pulmonary fibrosis and other progressive ILDs

Use the GAP index - the three-tier staging system from Annals of Internal Medicine, 2012. It combines four variables:

Stage I (0-3 points): median survival ~5 years. Stage II (4-5 points): ~4 years. Stage III (6-8 points): ~2 years. Refer at Stage I with documented decline. List at Stage II or III. Additionally, refer immediately if FVC drops 10% or DLCO drops 15% over 6 months regardless of stage, or if the patient develops pulmonary hypertension on echo.

Pulmonary arterial hypertension (PAH)

Refer when the patient is on maximal PAH-specific therapy (typically triple therapy including a prostacyclin) and remains in WHO functional class III-IV, has REVEAL score high risk, or has right heart failure signs. Do not wait for syncope - by that point right ventricular function may be irreversibly damaged.

Cystic fibrosis and bronchiectasis

Refer when FEV1 falls below 30% predicted, or when there is rapid FEV1 decline especially in young female patients, or 6MWD below 400 metres, or need for supplemental oxygen or non-invasive ventilation. In India, non-CF bronchiectasis follows the same triggers.

Post-COVID and post-TB fibrosis (Indian context)

For post-COVID lung damage, transplant is very rare - see our detailed post-COVID lung damage treatment guide. The practical trigger for referral is still needing supplemental oxygen for daily activity 3-6 months after infection with lung function that is not improving. For post-TB destroyed lung, refer when there is bilateral disease with FEV1 below 30% or single-lung disease with pulmonary hypertension, and infection has been controlled for at least 6 months.

The universal red-flag signs (regardless of underlying diagnosis)

Beyond the disease-specific criteria, certain warning signs should trigger a transplant referral the same week they appear - not after the next exacerbation, not after the next admission:

• Need for supplemental oxygen at rest or with minimal activity
• Progressive drop in FVC or DLCO over months despite optimal therapy
• Hospitalisations for respiratory failure, especially requiring non-invasive ventilation or ICU care
• Rising pulmonary artery pressures on echocardiogram or right heart catheterisation
• Weight loss, increasing breathlessness on minimal exertion, or new resting tachycardia
• 6-minute walk distance below 350 metres, or a fall of more than 50 metres over 6 months
• An acute event - sudden deterioration that places the patient on mechanical ventilation or ECMO
• Any patient with end-stage lung disease who mentions they are “afraid of dying at home” - that is a clinical cue, not just emotion

The wrong outcome is the patient who arrives at our ICU on a ventilator with no prior contact. That outcome is almost always preventable with an earlier referral.

Who is not a candidate

Transplant is not the right answer for every patient with severe lung disease. The following are usually contraindications per the ISHLT 2021 consensus:

Absolute contraindications

• Active malignancy other than localised skin cancer (typically requires 2-5 year disease-free interval depending on cancer type)
• Active infection outside the lungs that cannot be cleared before surgery
• Severe untreatable disease in another vital organ - heart, liver or kidney - unless combined transplant is being considered
• Active substance use: tobacco, cannabis, harmful alcohol use, illicit drugs (documented 6-month abstinence typically required)
• Severe uncorrectable atherosclerotic disease with end-organ dysfunction
• Inability to comply with lifelong immunosuppression or follow-up (medical, psychological, or social reasons - assessed compassionately, individually)

Relative contraindications (often surmountable)

• Age above ~70 years (case-by-case; not a strict cutoff)
• BMI above 32 or below 17 - weight optimisation programme runs 3-12 months
• Poorly controlled diabetes (HbA1c above 7.5%) - optimise then reassess
• Severe deconditioning or sarcopenia - pulmonary rehab first
• Chronic osteoporosis with fragility fractures - treat and reassess
• Untreated psychiatric illness or lack of caregiver - address first, transplant later

Most contraindications are relative, not absolute. A patient who quits smoking and proves 6 months of abstinence may become a candidate. A patient with kidney dysfunction may be assessed for combined lung-and-kidney transplant. Each case is reviewed individually by Dr. Manjunath M Negigoudara and the KIMS multi-disciplinary team - rejection on a single line item is rare.

What the evaluation actually involves

The work-up has four objectives:

1. Confirm the diagnosis and the stage of disease
2. Establish that there are no contraindications
3. Match the patient with the right type of transplant (single lung, bilateral lung, or combined heart-and-lung)
4. Build the donor compatibility profile (blood group, HLA typing, anti-HLA antibodies, viral status)

What the work-up looks like in practice at KIMS Electronic City

Evaluation includes: pulmonary function tests including DLCO, high-resolution CT chest, echocardiogram with right ventricular assessment, right heart catheterisation in selected cases, full-body imaging to exclude malignancy, 6-minute walk test with oximetry, dental and ENT clearance, infectious disease screening (HIV, hepatitis B and C, tuberculosis, CMV, EBV, VDRL), nutritional and psychosocial review, and dietitian consultation. For most ambulatory patients this takes 1-3 weeks; for unstable patients on ECMO, we compress it into days.

The pre-transplant evaluation cost at KIMS Electronic City is approximately ₹4.5-6 lakh. See our lung transplant cost in India and financing guide for the full cost breakdown and insurance mechanics.

What happens after listing

Once a patient is accepted, they are added to the national organ allocation list maintained by NOTTO (National Organ and Tissue Transplant Organization) and the regional ROTTO. In Karnataka, allocation is managed by Jeevasarthakathe (the state organ transplant programme). Allocation is based on blood group, body size, time on the list, and medical urgency. Waiting times in India range from a few weeks (for blood group AB, small donor, urgent need) to several months (for blood group O, large recipients, stable patients).

The goal during the wait is to keep the patient as fit as possible - pulmonary rehabilitation, nutritional support, vaccinations, prompt treatment of any infections, and tight control of cardiovascular risk factors. Patients who arrive at surgery in better shape recover faster, leave the ICU sooner, and have markedly better one-year outcomes. Where the patient deteriorates faster than a donor appears, ECMO can bridge them to transplant.

Why work with Dr. Manjunath M Negigoudara at KIMS Electronic City

Choosing where to be evaluated matters as much as the decision to be evaluated. A lung transplant is not a one-off procedure - it is a multi-year clinical relationship spanning workup, surgery, ICU care, immunosuppression, rejection monitoring, and airway complication management.

Dr. Manjunath M Negigoudara is the Transplant Pulmonologist leading the medical arm of the KIMS Electronic City lung transplant programme. His training includes:

• MBBS (Gold Medalist) - Bangalore Medical College
• MD Pulmonary Medicine - JSS Medical College
• DNB Respiratory Medicine - National Board of Examinations
• FIP - Fellowship in Interventional Pulmonology - Manipal Hospitals
• Karnataka Medical Council Reg. No. 116911

Dr. Manjunath has personally managed 250+ lung transplant cases within a KIMS programme that has completed 750+ transplants across organs - one of Asia’s largest thoracic transplant programmes. He holds international faculty appointments at ISHLT, ESOT, INSHLT and NAPCON. He was faculty at ISHLT 2024 Prague and presented India’s first successful Redo Double Lung Transplantation at ESOT 2025 London.

For related consultations, see our companion service pages:

• Best lung transplant doctor in Bangalore - the medical arm of the KIMS programme
• Transplant pulmonologist in Bangalore
• Best pulmonologist in Electronic City
• Full clinical profile of Dr. Manjunath M Negigoudara

The most important point - and the honest answer to the opening question

If you or your treating physician are even considering whether transplant might be relevant, that is the right moment for a specialist opinion - not later. An early conversation almost always helps: in many cases Dr. Manjunath tells patients they have 1-2 years of medical therapy left before transplant is required, which gives time to plan, build family support, and stay on the watch list. In other cases the conversation prompts immediate listing that saves a life.

Have we waited too long? Rarely, if you are ambulatory and still not on high-flow oxygen. Come in now.

Is it too early to consider this? Almost never. An early evaluation buys time and knowledge, not commitment.

The wrong outcome is the patient who arrives at our ICU on a ventilator with no prior contact, where we are forced to do an emergency evaluation under ECMO with markedly worse odds. That outcome is almost always preventable with an earlier referral.

Call +91 79937 41199 or WhatsApp Dr. Manjunath for an initial conversation. Records can be reviewed remotely before a formal in-person visit.